| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. | Director | Stock Option (Right to Buy) | 14,684 | $507,804 | $33.00 | 01 Jan 2026 | Direct |
| Apellis Pharmaceuticals, Inc. | Director | Common Stock | 17,051 | $402,915 | $23.63 | 01 Jan 2026 | Direct |
| SPRUCE BIOSCIENCES, INC. | Director | Stock Option (Right to Buy) | 3,400 | 11 Dec 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| APLS | Apellis Pharmaceuticals, Inc. | 01 Jan 2026 | 2 | $0 | 4 | Director | 05 Jan 2026, 16:35 |
| SPRB | SPRUCE BIOSCIENCES, INC. | 11 Dec 2025 | 1 | $0 | 4 | Director | 15 Dec 2025, 18:46 |
| SPRB | SPRUCE BIOSCIENCES, INC. | 11 Dec 2025 | 0 | $0 | 3 | Director | 15 Dec 2025, 18:44 |
| APLS | Apellis Pharmaceuticals, Inc. | 08 Jan 2025 | 2 | +$507,804 | 4 | Director | 10 Jan 2025, 17:39 |
| APLS | Apellis Pharmaceuticals, Inc. | 08 Jan 2025 | 0 | $0 | 3 | Director | 10 Jan 2025, 17:38 |